Skip to Main Content

Good day to you. This is Meghana of the Readout, filling in for Ed in this Wednesday edition of Pharmalittle. Here’s what’s happening in PharmaLand:

San Diego’s Neurocrine Biosciences won approval for its drug targeting tardive dyskinesia — a movement disorder seen in patients taking antipsychotic medication. This is the company’s first drug approval. Its stock leapt nearly 25 percent in premarket trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!